Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rena M Conti

Showing results (1-10 of 133) with videos related to

Pageof 14
Sort By:
JAMA|October 17, 2013
Drug discount program--replyRena M Conti
Journal of Oncology Practice|September 13, 2017
Biosimilars: Reimbursement Issues in Your Oncology PracticeRena M Conti
Annals of Internal Medicine|October 1, 2019
Financial Toxicity of Prescription DrugsRena M Conti
Journal of Oncology Practice|September 9, 2016
Expanding the Scope of the National Practice Oncology Benchmark Would Be a Critical Source for Understanding Outpatient Oncology Practice Costs and Profits in a Time of ChangeRena M Conti
Human Vaccines|August 11, 2010
Advances in economics to further inform investments in vaccine developmentRena M Conti
Clinical Advances in Hematology & Oncology : H&O|August 19, 2014
Eliminate cost-plus reimbursement for drugsRena M Conti
Clinical Advances in Hematology & Oncology : H&O|June 3, 2008
The societal benefit of nonprofit biotechnology companiesRena M Conti
Journal of Oncology Practice|May 20, 2014
Problems with public reporting of cancer quality outcomes dataPaul Goldberg, Rena M Conti
Journal of Managed Care & Specialty Pharmacy|April 26, 2022
Ensuring a high-quality and resilient supply chain of essential medications means paying moreT Joseph Mattingly, Rena M Conti
Journal of Oncology Practice|October 16, 2014
Improving outpatient oncology practice: several steps into a long journeyRena M Conti, Peter B Bach
Pageof 14

Showing results (1-10 of 133) with videos related to

Sort By:
Pageof 14
JAMA|October 17, 2013
Drug discount program--replyRena M Conti
Journal of Oncology Practice|September 13, 2017
Biosimilars: Reimbursement Issues in Your Oncology PracticeRena M Conti
Annals of Internal Medicine|October 1, 2019
Financial Toxicity of Prescription DrugsRena M Conti
Journal of Oncology Practice|September 9, 2016
Expanding the Scope of the National Practice Oncology Benchmark Would Be a Critical Source for Understanding Outpatient Oncology Practice Costs and Profits in a Time of ChangeRena M Conti
Human Vaccines|August 11, 2010
Advances in economics to further inform investments in vaccine developmentRena M Conti
Clinical Advances in Hematology & Oncology : H&O|August 19, 2014
Eliminate cost-plus reimbursement for drugsRena M Conti
Clinical Advances in Hematology & Oncology : H&O|June 3, 2008
The societal benefit of nonprofit biotechnology companiesRena M Conti
Journal of Oncology Practice|May 20, 2014
Problems with public reporting of cancer quality outcomes dataPaul Goldberg, Rena M Conti
Journal of Managed Care & Specialty Pharmacy|April 26, 2022
Ensuring a high-quality and resilient supply chain of essential medications means paying moreT Joseph Mattingly, Rena M Conti
Journal of Oncology Practice|October 16, 2014
Improving outpatient oncology practice: several steps into a long journeyRena M Conti, Peter B Bach
Pageof 14